Phaseline

Targets › KIR2DL3

KIR2DL3 (Killer cell immunoglobulin-like receptor 2DL3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology.

Receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). Inhibits the activity of NK cells thus preventing cell lysis. (UniProt, P43628)

Open in Phaseline: the race on KIR2DL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dana-Farber Cancer InstituteLirilumab
Killer cell immunoglobulin-like receptor 2DL1 inhibitor; Killer cell immunoglobulin-like receptor 2DL2 inhibitor; Killer cell immunoglobulin-like receptor 2DL3 inhibitor
KIR2DL1, KIR2DL3Phase 2Squamous Cell Carcinoma of the Head and Neck–

Conditions

Squamous Cell Carcinoma of the Head and Neck (1)

Modalities

antibody (1)

Companies

Dana-Farber Cancer Institute (1)

Related targets

KIR2DL1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.